Camber Launches Generic Neurontin® Oral Solution
Piscataway, NJ, July 19, 2024 – Camber Pharmaceuticals is pleased to announce the addition of Gabapentin Oral Solution to its product line. Camber also offers Gabapentin Tablets and Capsules.
Gabapentin Oral Solution is indicated for:
-
-
- Management of Postherpetic Neuralgia in adults
- Adjunctive therapy in the treatment of partial onset seizures, with and without secondary generalization, in adults and pediatric patients 3 years and older with epilepsy
-
Gabapentin Oral Solution is available in a 470 mL bottle with a concentration of 250 mg per 5 mL.
To learn more about Gabapentin Oral Solution, please visit https://www.camberpharma.com/gabapentinoralsolution
Recent articles
- Camber’s Parent Company, Hetero, Partners with the Gates Foundation to Supply Generic Lenacapavir for HIV Prevention
- Camber Adds 800 mg Darunavir Tablets to Product Family
- Camber Expands Portfolio with 10 New Generic Drug Launches in Q3 2025
- Camber Launches Indomethacin Suppositories
- Camber Launches Voriconazole for Injection
- Camber Launches Magnesium Sulfate Injection





